At a glance
ClinicalIndex Comparison RecordN/ACompleted· 331 enrolled
Drug / intervention
Tildrakizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Observational Study to Assess the Effectiveness, Safety Profile and Real-life Prescribing and Utilization Patterns of Tildrakizumab (Ilumetri®) in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice. (SAIL)
In Brief
An observational study evaluating Tildrakizumab for Plaque Psoriasis. Completed, enrolled 331 participants across 41 sites in 6 countries.
Detailed Summary
The observational, non-interventional study will assess the efficacy, safety, prescription and utilization patterns of Tildrakizumab in participants with moderate to severe plaque psoriasis in routine clinical practice.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesAustria, Belgium, France, Germany, Italy, Netherlands
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
Enrollment StartOct 2019
First PostedDec 2019
Primary CompletionMay 2024
TodayJul 2026
First PostedDec 18, 2019
Enrollment StartOct 30, 2019
Primary CompletionMay 2, 2024
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 6.5 years ago
Interventions
Tildrakizumabdrug
The study physicians will choose the treatment independently of the enrolment in the study according to routine care.